Blaze Bioscience, Inc. is a Seattle-based, privately held biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patients. The company was founded in 2010 to develop and commercialize the Tumor Paint technology. Tumor Paint provides real-time, high-resolution intraoperative visualization of cancer cells, enabling better detection and more complete and precise surgical resection of cancer. The first Tumor Paint product candidate, which is a combination of a targeting peptide and a fluorescent beacon, is under development for multiple solid tumors.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/11/12 | $5,000,000 | Series A | ||
| 02/22/13 | $8,500,000 | Series A |
